Roth Capital Lowers Earnings Estimates for Nuvectis Pharma
Nuvectis Pharma, Inc. (NASDAQ:NVCT – Free Report) – Research analysts at Roth Capital cut their FY2028 earnings estimates for shares of Nuvectis Pharma in a note issued to investors on Tuesday, February 25th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of $3.23 for the year, down from […]
Nuvectis Pharma, Inc. (NASDAQ:NVCT – Free Report) – Research analysts at Roth Capital cut their FY2028 earnings estimates for shares of Nuvectis Pharma in a note issued to investors on Tuesday, February 25th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of $3.23 for the year, down from […]
